CERS

Cerus Corporation (CERS) | Rumor.io

Cerus

CERS

Attention (50-day avg)0%

Attention rank (50-day avg)#3,179

Bullish sentiment (50-day avg)66%

Price to earnings ratio-30.5

Market capitalization493.7M

Earnings per share-0.03

Dividend yield (TTM)—

Revenue (annual)206.1M

Net income (annual)-15.6M

Social

What share of all stock conversation is about CERS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 4

$CERS has broken out with strong volume and an RSI in the sweet spot, indicating excitement in the charts.
The stock is considered bullish with a conviction rating of 65/100, driven by a Q1 earnings and a 4-year French blood supply deal.
$CERS is expected to continue its uptrend, with support holding above key levels and sustained underlying demand, but overhead supply zones remain a key area to watch.

Generated by AI

Sentiment

Of the messages about CERS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +40	89.59% +7.85
Bearish	—	0%	0% -40	10.41% -7.85

Bullish· May 1

$CERS is experiencing a significant breakout, surging to $2.72 with a 34.08% increase, driven by institutional accumulation and strong Q1 product revenue growth.
The stock is showing strong momentum, with a 26.35% price increase, and is expected to reach $343.72, making it a potential high-growth compounder.
$CERS is poised for new highs, with positive earnings expectations, massive expanding contracts, and approval for red blood cell use by the end of the year, making it a promising investment opportunity.

Bearish· Mar 19

The company is facing significant losses, with no revenues and a large cash burn, potentially leading to a stock offering that could dilute existing shareholders.
Insiders are selling their shares, indicating a lack of confidence in the company's prospects.
The company's warrants are now in the money, which could lead to massive dilution and a significant drop in the stock price.

Generated by AI

Topics

Of the messages about CERS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	25.23%
Analysts	—	—	—	10.94%
Technical Analysis	—	—	—	43.47%
Earnings	—	—	—	3.34%
Controversies	—	—	—	0%
Macro	—	—	—	17.02%

Earnings· Oct 30

Cerus Corporation ($CERS) reported a loss of $0.13 per share, missing the consensus estimate of a loss of $0.11 per share.
The company's revenue of $18.02 million beat the consensus estimate by $0.34 million.
Cerus Corporation reaffirmed its full-year 2019 revenue guidance despite missing the earnings per share (EPS) consensus estimate.

Announcements· Mar 19

Cerus Corporation announced positive topline results for the Phase 3 clinical trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients, meeting its primary efficacy endpoint.
The trial demonstrated non-inferiority for INTERCEPT RBCs compared to standard blood components, and the safety endpoint showed no significant difference in treatment-emergent adverse events.
Cerus Corporation's stock was halted for news pending, and trading will resume shortly, with the company also announcing plans to raise $150 million through a mixed shelf offering.

Technical Analysis· May 1

The 1-minute chart of CERS shows a failed breakout attempt, where the stock sold off after reaching 3.14, potentially due to the stock's large float of 160 million shares.
The stock's momentum is affected by its large market capitalization, which can lead to waves of volatility rather than true breakouts, according to market observations.
Technical analysis suggests that CERS is technically bullish, with potential targets at 3.15, 3.89, and 4.57, assuming the market remains positive.

Generated by AI

Community

Of the messages about CERS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	20%	28.57%	30%	32.58%
Newcomers	80%	71.43%	70%	67.42%

Regulars· Mar 19

Cerus Corporation has announced positive topline results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients, meeting its primary efficacy endpoint.
The successful trial is the basis for Cerus' application for European approval (EU) of the INTERCEPT Blood System, which has already demonstrated non-inferiority in two previous Phase 3 trials.
The company's stock, $CERS, saw significant trading volume and price movements, with a 17.42% increase on the day of the announcement.

Newcomers· May 1

New investors are focused on the current price of Cerus Corporation, noting it's around $2.90, with support at $2.55 and potential resistance at $3.07.
Others are highlighting the company's transition from a biotech to a medical device business, emphasizing its cash flow and ironclad grip on half of the U.S. blood supply.
Some analysts are predicting a significant turnaround for Cerus, citing 23% revenue growth and a potential catalyst for the stock, with one analyst seeing 39% more upside.

Generated by AI

News

Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS)

1mo agoSeeking Alpha

Cerus Corp chief legal officer sells $89,529 in company stock.

1mo agoInvesting.com

BTIG Remains a Buy on Cerus (CERS)

Tipranks Press Release.

1mo agoThe Globe and Mail

Cerus earnings beat by $0.02, revenue topped estimates

2mo agoInvesting.com

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

2mo agoYahoo Finance

Earnings call transcript: Cerus beats Q2 2026 estimates but shares fall after hours

2mo agoInvesting.com

Also Discussed

Investors talking about CERS also mention

#	Name	Attention
1	Compugen LtdCGEN	0%new
2	Codexis Inc.CDXS	0%0
3	Halozyme Therapeutics Inc.HALO	0%0
4	XOMA CorporationXOMA	0%0
5	BDSI - BioDelivery Sciences International, Inc.	——
6	Agenus Inc.AGEN	0.01%-0.01
7	FOLD - Amicus Therapeutics, Inc.	——
8	Design Therapeutics, Inc.DSGN	0%0
9	Fate Therapeutics Inc.FATE	0%new
10	EUDA Health Holdings LimitedEUDA	0%new

Cerus Corporation

Healthcare
Medical Devices

Cerus Corporation is a biomedical products company focused on blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform designed to help safeguard donated blood components intended for transfusion. Its current product line includes systems for platelets and plasma, and it also supports blood centers, hospitals, and other healthcare institutions that rely on treated blood products. Cerus Corporation operates within the healthcare and medical technology markets, with its products used to reduce the risk of blood-borne pathogens while preserving the therapeutic value of transfused components. Headquartered in Concord, California, Cerus Corporation is dedicated to advancing technologies that support safer blood supply workflows across clinical settings.

Website

Location

1220 Concord Avenue

Concord, CA, 94520

United States

Social

What share of all stock conversation is about CERS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 4

$CERS has broken out with strong volume and an RSI in the sweet spot, indicating excitement in the charts.
The stock is considered bullish with a conviction rating of 65/100, driven by a Q1 earnings and a 4-year French blood supply deal.
$CERS is expected to continue its uptrend, with support holding above key levels and sustained underlying demand, but overhead supply zones remain a key area to watch.

Generated by AI

Sentiment

Of the messages about CERS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +40	89.59% +7.85
Bearish	—	0%	0% -40	10.41% -7.85

Bullish· May 1

$CERS is experiencing a significant breakout, surging to $2.72 with a 34.08% increase, driven by institutional accumulation and strong Q1 product revenue growth.
The stock is showing strong momentum, with a 26.35% price increase, and is expected to reach $343.72, making it a potential high-growth compounder.
$CERS is poised for new highs, with positive earnings expectations, massive expanding contracts, and approval for red blood cell use by the end of the year, making it a promising investment opportunity.

Bearish· Mar 19

The company is facing significant losses, with no revenues and a large cash burn, potentially leading to a stock offering that could dilute existing shareholders.
Insiders are selling their shares, indicating a lack of confidence in the company's prospects.
The company's warrants are now in the money, which could lead to massive dilution and a significant drop in the stock price.

Generated by AI

Topics

Of the messages about CERS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	25.23%
Analysts	—	—	—	10.94%
Technical Analysis	—	—	—	43.47%
Earnings	—	—	—	3.34%
Controversies	—	—	—	0%
Macro	—	—	—	17.02%

Earnings· Oct 30

Cerus Corporation ($CERS) reported a loss of $0.13 per share, missing the consensus estimate of a loss of $0.11 per share.
The company's revenue of $18.02 million beat the consensus estimate by $0.34 million.
Cerus Corporation reaffirmed its full-year 2019 revenue guidance despite missing the earnings per share (EPS) consensus estimate.

Announcements· Mar 19

Cerus Corporation announced positive topline results for the Phase 3 clinical trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients, meeting its primary efficacy endpoint.
The trial demonstrated non-inferiority for INTERCEPT RBCs compared to standard blood components, and the safety endpoint showed no significant difference in treatment-emergent adverse events.
Cerus Corporation's stock was halted for news pending, and trading will resume shortly, with the company also announcing plans to raise $150 million through a mixed shelf offering.

Technical Analysis· May 1

The 1-minute chart of CERS shows a failed breakout attempt, where the stock sold off after reaching 3.14, potentially due to the stock's large float of 160 million shares.
The stock's momentum is affected by its large market capitalization, which can lead to waves of volatility rather than true breakouts, according to market observations.
Technical analysis suggests that CERS is technically bullish, with potential targets at 3.15, 3.89, and 4.57, assuming the market remains positive.

Generated by AI

Community

Of the messages about CERS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	20%	28.57%	30%	32.58%
Newcomers	80%	71.43%	70%	67.42%

Regulars· Mar 19

Cerus Corporation has announced positive topline results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients, meeting its primary efficacy endpoint.
The successful trial is the basis for Cerus' application for European approval (EU) of the INTERCEPT Blood System, which has already demonstrated non-inferiority in two previous Phase 3 trials.
The company's stock, $CERS, saw significant trading volume and price movements, with a 17.42% increase on the day of the announcement.

Newcomers· May 1

New investors are focused on the current price of Cerus Corporation, noting it's around $2.90, with support at $2.55 and potential resistance at $3.07.
Others are highlighting the company's transition from a biotech to a medical device business, emphasizing its cash flow and ironclad grip on half of the U.S. blood supply.
Some analysts are predicting a significant turnaround for Cerus, citing 23% revenue growth and a potential catalyst for the stock, with one analyst seeing 39% more upside.

Generated by AI

Cerus

Social

May 4

Bullish· May 1

Bearish· Mar 19

Earnings· Oct 30

Announcements· Mar 19

Technical Analysis· May 1

Regulars· Mar 19

Newcomers· May 1

Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS)

Cerus Corp chief legal officer sells $89,529 in company stock.

BTIG Remains a Buy on Cerus (CERS)

Cerus earnings beat by $0.02, revenue topped estimates

Cerus: Q2 Earnings Snapshot

Earnings call transcript: Cerus beats Q2 2026 estimates but shares fall after hours

Also Discussed

Cerus Corporation

Company Information

Location

Cerus: This Blood-Safety Underdog Should Be Earning More Respect (NASDAQ:CERS)

Cerus Corp chief legal officer sells $89,529 in company stock.

BTIG Remains a Buy on Cerus (CERS)

Cerus earnings beat by $0.02, revenue topped estimates

Cerus: Q2 Earnings Snapshot

Earnings call transcript: Cerus beats Q2 2026 estimates but shares fall after hours

Also Discussed

Social

May 4

Bullish· May 1

Bearish· Mar 19

Earnings· Oct 30

Announcements· Mar 19

Technical Analysis· May 1

Regulars· Mar 19

Newcomers· May 1